See our Editor's picks below and explore all our content on VJOncology.com!
ESMO 2022: highlights from the Presidential Symposium Solange Peters, MD, PhD provides an overview of key trials presented during the Presidential Symposium of the ESMO 2022 congress.
Mechanism of action for air pollution-induced NSCLC Charles Swanton, FRCP, BSc, PhD, talks on how increasing particulate matter levels are associated with increased risk of EGFR mutant NSCLC, providing evidence to limit air pollution and opportunities for molecular targeted cancer prevention.
KEYNOTE-412: pembrolizumab with CRT vs placebo plus CRT for locally advanced HNSCC Jean-Pascal Machiels, MD, PhD, discusses results from the KEYNOTE-412 trial, which evaluated pembrolizumab with chemoradiation therapy (CRT) for advanced head and neck squamous cell carcinoma.
EV-103 Cohort K: enfortumab vedotin +/- pembro in untreated cis-ineligible patients with mUC Jonathan Rosenberg, MD demonstrates that enfortumab vedotin plus pembrolizumab showed high overall response rates with rapid responses in cohort K of the EV-103 trial.
Final OS results from PAOLA-1 evaluating 1L maintenance olaparib plus bevacizumab Nicoletta Colombo, MD, PhD, discusses the final overall survival (OS) results from the PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with advanced ovarian cancer.
Patient-reported outcomes from DESTINY-Breast04 Naoto Ueno, MD, PhD talks on the patient reported outcomes from the DESTINY-Breast04 trial, which confirm the quality of life benefit of T-DXd versus treatment of physician’s choice for patients with HER2-low metastatic breast cancer.
Check out our disease channels!
Check out more developments across different disease types with our dedicated disease channels, featuring expert interviews, podcasts, roundtable discussions and more
